A Cross-sectional Study of Ocular Manifestations During the Covid-19 Pandemic in Hubei Province

April 7, 2024 updated by: Min Ke, Zhongnan Hospital
To investigate the clinical features of ocular manifestations during the novel coronavirus pneumonia pandemic in Hubei at the end of 2022

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

During late 2022 COVID-19 pandemic ocular discomforts were common in people with mild systemic symptoms, but most resolve on their own without any treatment. The disease spectrum of ophthalmology outpatient clinics is affected by the COVID-19 pandemic. In our study, we observed that the incidence of keratitis and acute angle-closure glaucoma in Phase A was significantly higher than that in Phase B and C.

Study Type

Observational

Enrollment (Actual)

16000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Hubei
      • Wuhan, Hubei, China, 430071
        • Zhongnan Hospital of Wuhan University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

People from Hubei Province, China

Description

Inclusion Criteria:

  • 1. 2022.12.7 to 2023.2.6 People surveyed by wechat Questionnaire Star 2. 2021.12.7 to 2022.1.6 and 2022.11.7 to 2023.1.6 Patients who received ophthalmology treatment in Zhongnan Hospital of Wuhan University and Qichun People's Hospital

Exclusion Criteria:

  • 1. currently hospitalized patients. 2. severe patients. 3. Incomplete information. 4. cannot be contacted by telephone. 5. Refuse questionnaire survey. 6.The electronic medical record information is incomplete. 7. Those who do not go to the ophthalmic clinic after registration. 8.severe patients. 9. Cannot be contacted by phone.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
the pandemic period (Phase A)
Other: NOT
NOT
the prevention and control periods (Phase B: November 7, 2022 to December 6, 2022 ).
the prevention and control periods (Phase B: November 7, 2022 to December 6, 2022 and Phase C: December 7, 2021 to January 6, 2022).
Other: NOT
NOT
the prevention and control periods (Phase C: December 7, 2021 to January 6, 2022).
the prevention and control periods (Phase B: November 7, 2022 to December 6, 2022 and Phase C: December 7, 2021 to January 6, 2022).
Other: NOT
NOT

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Questionnaire data were collected and statistically analyzed.
Time Frame: 1/4/2024-30/4/2024
Information on demographic characteristics, COVID-19 pathogen test results, Covid-19 related systemic symptoms, ocular symptoms and eye discomfort medication was collected from questionnaires during the pandemic period (Phase A: December 7, 2022 to January 6, 2023, 1968 patients). Electronic medical records in the ophthalmic outpatient department of Zhongnan Hospital of Wuhan University and its medical union hospital- Qichun County People's Hospital were extracted during the pandemic period (Phase A) and the prevention and control periods (Phase B: November 7, 2022 to December 6, 2022 and Phase C: December 7, 2021 to January 6, 2022). The demographic, epidemiological, and clinical information of patients were compared.
1/4/2024-30/4/2024

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Zhongnan Hospital

Collaborators

Qichun People's Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2024

Primary Completion (Actual)

February 18, 2024

Study Completion (Estimated)

April 30, 2024

Study Registration Dates

First Submitted

March 21, 2024

First Submitted That Met QC Criteria

April 7, 2024

First Posted (Actual)

April 9, 2024

Study Record Updates

Last Update Posted (Actual)

April 9, 2024

Last Update Submitted That Met QC Criteria

April 7, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 20240307

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19

Clinical Trials on NOT

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe